CNS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.215 USD | +5.39% |
|
+6.44% | -83.07% |
| Apr. 23 | Transcript : CNS Pharmaceuticals, Inc. - Special Call | |
| Apr. 01 | CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 64.98 | 41.13 | 19.61 | 3.203 | 6.666 |
| Enterprise Value (EV) 1 | 57.74 | 27.53 | 14.99 | -6.443 | 6.418 |
| P/E ratio | -13.9 x | -3.13 x | -1.32 x | -0.21 x | -0.25 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -15,070,930 x | -2,915,095 x | -1,069,980 x | 422,334 x | -340,269 x |
| EV / FCF | -21.8 x | -6.44 x | -1.93 x | 1.12 x | -0.8 x |
| FCF Yield | -4.58% | -15.5% | -51.9% | 89% | -125% |
| Price to Book | 8.55 x | 3.04 x | 2.96 x | 0.48 x | -1.78 x |
| Nbr of stocks (in thousands) | 548 | 770 | 931 | 1,334 | 5,249 |
| Reference price 2 | 118.5 | 53.40 | 21.07 | 2.400 | 1.270 |
| Announcement Date | 3/12/20 | 2/12/21 | 3/3/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | -3.831 | -9.444 | -14.01 | -15.26 | -18.86 |
| EBIT 1 | -0.8818 | -3.833 | -9.455 | -14.03 | -15.27 | -18.87 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.392 | -3.877 | -9.458 | -14.04 | -15.27 | -18.85 |
| Net income 1 | -7.392 | -3.877 | -9.458 | -14.04 | -15.27 | -18.85 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -21.10 | -8.523 | -17.07 | -15.98 | -11.22 | -5.004 |
| Free Cash Flow 1 | 0.1111 | -2.646 | -4.273 | -7.777 | -5.734 | -8.003 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/12/20 | 2/12/21 | 3/3/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -3.813 | -2.793 | -2.782 | -3.564 | -3.419 | -4.025 | -4.534 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.814 | -2.795 | -2.784 | -3.566 | -3.42 | -4.021 | -4.523 |
| Net income 1 | -3.814 | -2.795 | -2.784 | -3.566 | -3.42 | -4.021 | -4.523 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -4.200 | -3.000 | -2.100 | -2.700 | -2.700 | -1.040 | -1.080 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/3/22 | 5/13/22 | 8/12/22 | 11/10/22 | 8/14/23 | 11/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.03 | - | - | - | - | - |
| Net Cash position 1 | - | 7.24 | 13.6 | 4.62 | 9.65 | 0.25 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 0.11 | -2.65 | -4.27 | -7.78 | -5.73 | -8 |
| ROE (net income / shareholders' equity) | 2,432% | -110% | -87.8% | -136% | -214% | -1,019% |
| ROA (Net income/ Total Assets) | -130% | -55.7% | -49.7% | -71.2% | -87.5% | -160% |
| Assets 1 | 5.67 | 6.956 | 19.02 | 19.7 | 17.46 | 11.79 |
| Book Value Per Share 2 | -1.300 | 13.90 | 17.50 | 7.110 | 5.030 | -0.7100 |
| Cash Flow per Share 2 | 0.6700 | 13.20 | 17.70 | 5.380 | 6.220 | 0.0900 |
| Capex | - | 0.02 | 0.02 | 0.01 | 0 | 0 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/12/20 | 2/12/21 | 3/3/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -83.07% | 2.29M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CNSP Stock
- Financials CNS Pharmaceuticals, Inc.
